Correlation of Anti-Müllerian Hormone with Polycystic Ovarian Disease and its Relation with Age

Sara Omer Muhammed; Chro Najmaddin Fattah

doi:10.24017/science.2019.ICHMS.5

Authors

Sara Omer Muhammed Obstetrics and Gynecology, Sulaimani Maternity Teaching Hospital, Sulaimani, Iraq
Chro Najmaddin Fattah Obstetrics and Gynecology, Sulaimani Maternity Teaching Hospital, School of Medicine, University of Sulaimani, Sulaimani, Iraq

Abstract

Polycystic ovarian disease (PCOD) is a common endocrine disorder of reproductive-aged women. Serum Anti-Müllerian hormone (AMH) increases in PCOD women due to increased follicle numbers. Objectives: The aim was to evaluate ovarian reserve by measuring level of AMH among PCOD women. Prospective cohort study was performed on 62 ladies who aged 25 to 40 years and diagnosed by Rotterdam criteria as PCOD in Sulaimani Maternity Teaching Hospital/Outpatient Gynecological Clinic during May 2018 to May 2019. Consents were obtained from patients for their inclusion. Inclusion criteria were age of 25-40 years and diagnosis of PCOD. The patients’ ages, body mass index (BMI) and level of AMH were recorded. Sample size estimation was performed by "GPower 3.1" and "IBM SPSS Statistics version 25" was used for analysis of data. P-value of (?0.05) was considered significant. The mean±SD (standard deviation) of age of women were 31.7±5 years. The majority of participants were housewives from inside of Sulaimani City and most of them were diagnosed to have PCOD through clinical features and results of ultrasonography. The mean±SD of BMI and AMH were 26.2±2.8 kg/m² (ranged from 21.3 to 33.2 kg/m²) and 4.76±3.51 ng/ml (ranged from 0.1-14.6 ng/ml) respectively. There was significant association between age of the participants and AMH and the association of BMI and AMH was not significant. The level of AMH is decreased with aging and it is higher among PCOD women due to increased follicle numbers. The level of AMH was not associated with BMI.

Keywords:

Anti-Müllerian hormone (AMH), Infertility, Polycystic ovarian disease (PCOD).

References

[1] T. WONGWANANURUK, N. PANICHYAWAT , S. INDHAVIVADHANA, M. RATTANACHAIYANONT, S. ANGSUWATHANA, K. TECHATRAISAK, ET AL. "ACCURACY OF ANTI-MÜLLERIAN HORMONE AND TOTAL FOLLICLES COUNT TO DIAGNOSE POLYCYSTIC OVARYSYNDROME IN REPRODUCTIVE WOMEN," TAIWAN J OBSTET GYNECOL., VOL. 57, NO.. 4, PP. 499-506, 2018.
https://doi.org/10.1016/j.tjog.2018.06.004
[2] R. HOMBURG, G. CRAWFORD. "THE ROLE OF AMH IN ANOVULATION ASSOCIATED WITH PCOS: A HYPOTHESIS," HUM REPROD., VOL. 29, NO. 6, PP. 1117-1121, 2014.
https://doi.org/10.1093/humrep/deu076
[3] N. N. JAHROMI, M. H. DABBAGHMANESH, P. BAKHSHAIE, M. E. PARSANEZHAD, Z. ANVAR, M. ALBORZI, ET AL. "ASSESSMENT OF OXYTOCIN LEVEL, GLUCOSE METABOLISM COMPONENTS AND CUTOFF VALUES FOR OXYTOCIN AND ANTI-MULLERIAN HORMONE IN INFERTILE PCOS WOMEN," TAIWAN J OBSTET GYNECOL., VOL. 57, NO. 4, PP. 555-559, 2018.
https://doi.org/10.1016/j.tjog.2018.06.015
[4] A. C. de Kat, F. J. Broekmans, J. S. Laven, Y. T. van der Schouw. "Anti-Müllerian Hormone as a marker of ovarian reserve in relation to cardio-metabolic health: A narrative review," Maturitas, vol. 80, no. 3, pp. 251-257, 2015.
https://doi.org/10.1016/j.maturitas.2014.12.010
[5] H. Aydo?mu?, S. Kelekçi, F. Elmal?, S. Aydo?mu?. "Can we use serum Anti-Mullerian hormone to differentiate the diagnosis between polycystic ovary syndrome patients and healthy women with polycystic ovarian morphology and regular menstrual cycles," Saudi Med J., vol. 39, no. 10, pp. 1011-1016, 2018.
https://doi.org/10.15537/smj.2018.10.23413
[6] A. KÖNINGER, A. KAMPMEIER, B. SCHMIDT, M. FRANK, T. STROWITZKI, R. KIMMIG, ET AL. "TRENDS IN ANTI-MÜLLERIAN HORMONE CONCENTRATIONS ACROSS DIFFERENT STAGES OF PREGNANCY IN WOMEN WITH POLYCYSTIC OVARY SYNDROME," REPROD BIOMED ONLINE, VOL. 37, NO. 3, PP. 367-374, 2018.
https://doi.org/10.1016/j.rbmo.2018.05.011
[7] C. Y. Yue, L. K. Y. Lu, M. Li, Q. L. Zhang, C. M. Ying. "Threshold value of anti-Mullerian hormone for the diagnosis of polycystic ovary syndrome in Chinese women," PLoS ONE, vol. 13, no. 8, pp. e0203129, 2018.
https://doi.org/10.1371/journal.pone.0203129
[8] L. Barbakadze, J. Kristasashvili. "Antimullerian hormone in cases of different reproductive pathologies," Georgian Med News, vol. 232-233, pp. 16-21, 2014.
[9] X. Shi, D. Peng, Y. Liu, X. Miao, H. Ye, J. Zhang. "Advantages of Serum Anti-Müllerian Hormone as a Marker for Polycystic Ovarian Syndrome," Lab Med., vol. 00, pp. 1-7, 2018.
[10] A. Moini, A. Arabipoor, M. Hemat, J. Ahmadi, R. Salman-Yazdi, Z. Zolfaghari. "The effect of weight loss program on serum anti-Müllerian hormone level in obese and overweight infertile women with polycystic ovary syndrome," Gynecol Endocrinol, vol. 35, no. 2, pp. 119-123, 2019.
https://doi.org/10.1080/09513590.2018.1499084
[11] X. Tian, X. Ruan, A. O. Mueck, D. Wallwiener, J. Wang, S. Liu, D. Yin, Y. Lu, Y. Zhang, H. Wu. "Serum anti-Mullerian hormone and insulin resistance in the main phenotypes of non-obese polycystic ovarian syndrome women in China," Gynecol Endocrinol., vol. 30, no. 11, pp. 836-839, 2014.
https://doi.org/10.3109/09513590.2014.943719